Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.

Abstract : INTRODUCTION: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) has been shown to be useful for staging and therapy response evaluation. The European Organization for Research and Treatment of Cancer (EORTC) and Positron Emission Tomography Response Criteria In Solid Tumors (PERCIST) criteria were compared in the evaluation of response assessment and prognostic factors were defined in a cohort of SCLC patients. METHODS: Twenty-nine consecutive patients with SCLC were included in this study. Sixteen patients had extensive disease and 13 had limited disease. All patients had chemotherapy, 21 had thoracic radiotherapy. FDG-PET/CT scans were performed before and after therapy to evaluate treatment response. Metabolic responses were assessed using the EORTC criteria and PERCIST criteria. Univariate and multivariate analysis were performed using a Cox model to investigate the association between progression-free and overall survival time with a number of covariates. RESULTS: There was perfect concordance between the EORTC and PERCIST criteria. Eight patients had a complete metabolic response (CMR), 9 had a partial metabolic response (PMR), 5 had stable metabolic disease (SMD) and 7 had progressive metabolic disease (PMD). Overall survival time in patients with CMR was significantly longer compared with patients who did not have CMR. The initial or delayed CMR and post-therapeutic standardized uptake value corrected for lean body mass were significantly associated with overall survival. CONCLUSION: CMR on post-therapeutic FDG-PET/CT in patients with SCLC is an important prognostic factor and may help decision making for therapeutic management.
Type de document :
Article dans une revue
Cancer Imaging, e-Med Limited, 2013, 13, pp.73-80. 〈10.1102/1470-7330.2013.0008〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00925526
Contributeur : Pierre Marquet <>
Soumis le : mercredi 8 janvier 2014 - 11:04:39
Dernière modification le : vendredi 16 février 2018 - 15:25:01

Lien texte intégral

Identifiants

Collections

Citation

David Ziai, Thomas Wagner, Assmae El Badaoui, Anne Hitzel, Jean-Baptiste Woillard, et al.. Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria.. Cancer Imaging, e-Med Limited, 2013, 13, pp.73-80. 〈10.1102/1470-7330.2013.0008〉. 〈inserm-00925526〉

Partager

Métriques

Consultations de la notice

83